Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2/Bad pathway

Mahmoud Alhosin1, Antonio J. León-González1, Israa Dandache1, Agnès Lelay1,2, Sherzad K. Rashid1, Claire Kevers3, Joël Pincemail4, Luc-Matthieu Fornecker2,5, Laurent Mauvieux5,6, Raoul Herbrecht2,5, & Valérie B. Schini-Kerth1

1CNRS UMR 7213 Laboratoire de Biophotonique et Pharmacologie, Université de Strasbourg, Faculté de Pharmacie, 74, route du Rhin, 67401 Illkirch, France, 2Oncologie et Hématologie, Hôpitaux Universitaires de Strasbourg, Avenue Molière, 67100 Strasbourg, France, 3University of Liège, Plant Molecular Biology and Biotechnology Unit, B22, Sart Tilman, B-4000 Liège, Belgium, 4Dept. of Cardiovascular Surgery and CREDEC, Pathology Tower B23, Sart Tilman, B-4000 Liège, Belgium, 5Université de Strasbourg, Faculté de Médecine, Strasbourg, France, 6Laboratoire d’Hématologie, Hôpitaux Universitaires de Strasbourg, Avenue Molière, 67100 Strasbourg, France.

Defect in apoptosis has been implicated as a major cause of resistance to chemotherapy observed in B cell chronic lymphocytic leukemia (B CLL). This study evaluated the pro-apoptotic effect of an anthocyanin-rich dietary bilberry extract (Antho 50) on B CLL cells from 30 patients and on peripheral blood mononuclear cells (PBMCs) from healthy subjects, and determined the underlying mechanism. Antho 50 induced concentration- and time-dependent pro-apoptotic effects in B CLL cells but little or no effect in PBMCs. Among the main phenolic compounds of the bilberry extract, delphinidin-3-O-glucoside and delphinidin-3-O-rutinoside induced a pro-apoptotic effect. Antho 50-induced apoptosis is associated with activation of caspase 3, down-regulation of UHRF1, a rapid dephosphorylation of Akt and Bad, and down-regulation of Bcl-2. Antho 50 significantly induced PEG-catalase-sensitive formation of reactive oxygen species in B CLL cells. PEG-catalase prevented the Antho 50-induced induction of apoptosis and related signaling. The present findings indicate that Antho 50 exhibits strong pro-apoptotic activity through redox-sensitive caspase 3 activation-related mechanism in B CLL cells involving dysregulation of the Bad/Bcl-2 pathway. This activity of Antho 50 involves the glucoside and rutinoside derivatives of delphinidin. They further suggest that Antho 50 has chemotherapeutic potential by targeting selectively B CLL cells.

Chronic lymphocytic leukemia (CLL), defined by the accumulation of pathogenic B cells, is still an incurable disease despite the recent development of novel therapeutic approaches. Dysregulation of apoptosis is a hallmark of CLL making this disease an ideal experimental model of malignancy due to the failure of apoptosis. The current knowledge about the mechanism responsible for dysregulation of apoptosis in CLL is still poor. High levels of the anti-apoptotic protein Bcl-2 have been found in several hematological malignancies, including CLL. Therefore, overexpression of Bcl-2 has been suggested to have a central role in defects of apoptosis and cell survival observed in CLL. The opportunity to induce apoptosis by targeting Bcl-2 protein and/or Bcl-2-regulating proteins such as Bad is therefore considered as a promising therapeutic approach in CLL. Several epidemiological studies have suggested that the consumption of fruits and vegetables can reduce the risk of developing cancer. Polyphenol-rich products have been reported to have potential chemopreventive and chemotherapeutic activities in cancer cells including CLL by targeting several apoptosis-regulating pathways. In this context, green tea and its active constituent epigallocatechin gallate (EGCG) have been shown to induce apoptosis in leukemic B cells isolated from CLL patients. At low concentrations, EGCG significantly increased apoptosis in CLL cells involving Bcl-2 down-regulation, caspase 3 activation and the dephosphorylation of VEGF.
receptors. Inhibition of the endogenous nitric oxide pathway causing caspase 3 activation during apoptosis has also been suggested to contribute to the pro-apoptotic effects of polyphenolic compounds such as derivatives of resveratrol and viniferin.

Beneficial effects of berries have been reported in several diseases such as cardiovascular diseases and cancer. Bilberry (Vaccinium myrtillus L.) is one of the richest dietary natural sources of anthocyanins which has been shown to have several therapeutic activities such as inhibition of angiogenesis and anti-cancer properties. Antho 50 is a bilberry extract composed of about 50% of anthocyanins which has previously been shown to be predominantly absorbed as glycosides from the stomach in rats. The aim of the present study was to evaluate the pro-apoptotic effects of this bilberry extract rich in anthocyanins on CLL cells from 30 patients and peripheral blood mononuclear cells (PBMCs) from 5 healthy subjects and, if so, to determine the signaling pathway involved.

Methods

Patients, cell separation, and culture conditions. All experiments were performed in accordance with the Declaration of Helsinki and approved local ethical guidelines. Patients received oral and written information on research and all signed a consent form approved by the Ethic Committee (Comité de Protection des Personnes “Est- Patients.” 1 place de l’Hôpital, 67091 Strasbourg Cedex, France). Cells were collected from 30 patients (21 male, 9 female) at the University Hospital of Strasbourg, France (Table 1). Median age of the patients was 69 years (range: 43–83 years). Median circulating lymphocytes count was 53.3 × 10^3/μL (range: 4.2–190.2 × 10^3/μL). Twenty-three patients were untreated for CLL while 7 had received 1 to 4 prior lines of chemotherapy. All these 7 patients were off-therapy for at least two months at time of sampling. Five peripheral blood samples have been sampled from donors and used in the study. Disease has been characterized in all patients by increased lymphocytes count in blood, typical cytological aspects of the cells and immunophenotyping showing a monotypic cell population with a Matutes score of 4 or 5. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll density-gradient centrifugation (Lymphocyte Separation Medium, MP Biomedicals). Cells were incubated at 1 to 2 × 10^6 cells/mL in RPMI 1640 medium containing 10% fetal bovine serum and incubated at 37 °C in an atmosphere of 5% CO2.

UPLC-PDA analysis. Bilberry anthocyanin purified extract, Antho 50, was kindly provided by FERLUX S. A. (Cournon d’Auvergne, France). Standards of cyanidin-3-O-gluoside, cyanidin-3-O-galactoside, cyanidin-3-O-rutinoside, delphinidin-3-O-glucoside, delphinidin-3-O-galactoside and delphinidin-3-O-rutinoside were purchased from Extrasynthese (Genay Cedex, France).

All experiments were performed according to the manufacturer’s instructions on PBMCs and B cells from CLL patients exposed to Antho 50 or to a pure anthocyanin at different concentrations and for different times. Apoptosis rates were then assessed by flow cytometry. At least 10,000 events were recorded and represented as dot plots.

Cell viability assay. Cells were seeded on 6-well plates at a density of 2 × 10^5 cells/well, grown for 24 h and exposed to Antho 50 at 75 μg/mL for different times. Cell viability ratio was determined by cell counting using the trypan blue exclusion method (Invitrogen). The viability rate was obtained by dividing the number of trypan blue-negative cells (viable cells) by the total number of cells.

Assessment of DNA fragmentation pattern. Genomic DNA was prepared according to the manufacturer’s instructions (Qiagen, Courtaboeuf, France).

| Table 1 | Clinical characteristics of the CLL patients |
|---------|-------------------------------------------|
| Patient no. | Sex | Age (y) | Absolute lymphocytosis, ×10^3/μL | Prior treatment status |
| 1 | F | 60 | 54.9 | Treated |
| 2 | M | 81 | 84.4 | Untreated |
| 3 | M | 77 | 43.8 | Untreated |
| 4 | M | 70 | 190.2 | Treated |
| 5 | M | 76 | 80.0 | Treated |
| 6 | M | 64 | 101.2 | Untreated |
| 7 | F | 73 | 66.1 | Untreated |
| 8 | F | 53 | 103.6 | Untreated |
| 9 | M | 68 | 6.9 | Untreated |
| 10 | M | 70 | 45.5 | Untreated |
| 11 | M | 77 | 56.9 | Untreated |
| 12 | M | 75 | 11.6 | Untreated |
| 13 | M | 71 | 58.0 | Untreated |
| 14 | M | 71 | 4.2 | Untreated |
| 15 | M | 82 | 11.9 | Untreated |
| 16 | M | 73 | 14.2 | Untreated |
| 17 | M | 78 | 25.2 | Untreated |
| 18 | F | 67 | 18.9 | Untreated |
| 19 | F | 43 | 7.4 | Untreated |
| 20 | M | 61 | 17.8 | Untreated |
| 21 | F | 66 | 35.9 | Treated |
| 22 | M | 61 | 32.5 | Untreated |
| 23 | M | 81 | 9.5 | Untreated |
| 24 | M | 83 | 182.6 | Untreated |
| 25 | M | 56 | 68.4 | Untreated |
| 26 | M | 68 | 31.8 | Treated |
| 27 | M | 57 | 61.9 | Untreated |
| 28 | M | 79 | 30.3 | Untreated |
| 29 | M | 67 | 21.5 | Untreated |
| 30 | F | 66 | 122.5 | Untreated |
Antho 50 reduces cell viability and induces selectively a concentration- and time-dependent apoptosis in B CLL cells. Cells were exposed to increasing concentrations of Antho 50 for 24 h or for 75 μg/mL for the indicated times. Apoptosis in B CLL cells (A, B) and in PBMCs (D) was assessed by flow cytometry using annexin V FITC/PI assay kit was performed. As indicated in Fig. 1A, a concentration-dependent increase in annexin V positive cells was observed in Antho 50-treated cells for 24 h and this effect reached significance at concentrations greater than 25 μg/mL of Antho 50. The percentage of annexin V positive cells reached approximately 75% at 75 μg/mL. Incubation of cells with 75 μg/mL of Antho 50 induced a time-dependent increase in annexin V positive cells with a significant effect observed already at 1 h (Fig. 1B) and which was associated with a reduction in cell viability (Fig. 1C).

To determine the selectivity of Antho 50, PBMCs from five healthy adult donors were incubated with Antho 50 for 24 h (Fig. 1D). Although Antho 50 at a concentration of 25 μg/mL significantly induced apoptosis in CLL cells by about 50% (Fig. 1A), no such

**Statistical Analysis.** Results are presented as mean ± SEM of at least three independent experiments. In the case of pairwise between group comparisons, statistical analysis was carried out using Student’s t test. Statistical analysis was also performed using a two-way analysis of variance (ANOVA) followed by a Bonferroni post-hoc test to compare differences. Significant differences are indicated as *P < 0.05, **P < 0.001, ***P < 0.0001.

**Results**

Antho 50 selectively induces apoptosis in B CLL cells.

Cells were grown in 6-well plates and treated with different concentrations of Antho 50 for different times. Cells were lysed with ice-cold RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5, and a protease inhibitor mixture tablet). Equal amounts of total proteins were separated on 10–12% polyacrylamide gel and electrophoretically transferred to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK), which were then blocked with 5% BSA (BioRad, Hercules, USA) for 1 h at room temperature. Membranes were then incubated with either a mouse monoclonal anti-UHRF1 (Proteogenix, Oberhausenbergen, France), a rabbit polyclonal anti-caspase 3, a rabbit polyclonal anti-p-Bad, a rabbit polyclonal anti p-Akt Ser473 (Cell Signaling Technology, Inc. Danvers, MA), a mouse monoclonal anti-p73 (BD Biosciences Pharmingen), a mouse monoclonal anti-p53 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), a mouse monoclonal anti-Bcl-2 (Millipore, Darmstadt, Germany) or a mouse monoclonal anti-β-tubulin or anti-β-actin antibody (Abcam, Paris, France), according to the manufacturer’s instructions at 4°C overnight. The membranes were then washed three times; 5 min each time with PBS. Membranes were thereafter incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (diluted to 1:10,000 for anti-mouse antibody and 1:5,000 for anti-rabbit antibody) at room temperature for 1 h. Membranes were then washed with PBS five times. Signals were detected by chemiluminescence using an enhanced chemiluminescence kit (GE Healthcare).

**Western blot analysis.** Cells were grown in 6-well plates and treated with different concentrations of Antho 50 for different times. Cells were lysed with ice-cold RIPA buffer (150 mM NaCl, 1% Triton X-100, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris-HCl, pH 7.5, and a protease inhibitor mixture tablet). Equal amounts of total proteins were separated on 10–12% polyacrylamide gel and electrophoretically transferred to nitrocellulose membranes (GE Healthcare, Buckinghamshire, UK), which were then blocked with 5% BSA (BioRad, Hercules, USA) for 1 h at room temperature. Membranes were then incubated with either a mouse monoclonal anti-UHRF1 (Proteogenix, Oberhausenbergen, France), a rabbit polyclonal anti-caspase 3, a rabbit polyclonal anti-p-Bad, a rabbit polyclonal anti p-Akt Ser473 (Cell Signaling Technology, Inc. Danvers, MA), a mouse monoclonal anti-p73 (BD Biosciences Pharmingen), a mouse monoclonal anti-p53 (Santa Cruz Biotechnologies, Santa Cruz, CA, USA), a mouse monoclonal anti-Bcl-2 (Millipore, Darmstadt, Germany) or a mouse monoclonal anti-β-tubulin or anti-β-actin antibody (Abcam, Paris, France), according to the manufacturer’s instructions at 4°C overnight. The membranes were then washed three times; 5 min each time with PBS. Membranes were thereafter incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (diluted to 1:10,000 for anti-mouse antibody and 1:5,000 for anti-rabbit antibody) at room temperature for 1 h. Membranes were then washed with PBS five times. Signals were detected by chemiluminescence using an enhanced chemiluminescence kit (GE Healthcare).

**Determination of the cellular formation of reactive oxygen species.** The oxidative fluorescent dye dihydroethidium (DHE) was used to evaluate the formation of reactive oxygen species (ROS). To determine the nature of ROS, cells were incubated either with superoxide dismutase (SOD, 500 U/mL), catalase (500 U/mL), or PEG-reactive oxygen species (ROS). To determine the nature of ROS, cells were incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (diluted to 1:10,000 for anti-mouse antibody and 1:5,000 for anti-rabbit antibody) at room temperature for 1 h. Membranes were then washed with PBS five times. Signals were detected by chemiluminescence using an enhanced chemiluminescence kit (GE Healthcare).

**Figure 1 | Antho 50 reduces cell viability and induces selectively a concentration- and time-dependent apoptosis in B CLL cells.** Cells were subjected to flow cytometry examination (BD FACSCalibur, Becton Dickinson, Franklin Lakes, NJ, USA). Histograms of 10,000 events were recorded per experiment.
Extracts-mediated cell death in cancer cells including leukaemia 17–20. Suppressor genes p53 regulation in B CLL cells independently of the status of tumor Antho 50 induces an early caspase 3 activation and UHRF1 down-regulation in CLL cells. The chemical analysis of Antho 50 bilberry extract indicated a polyphenol rich composition (513.20 ± 16.20 mg GAE/g) with a major content of anthocyanins (450.31 ± 5.70 mg/g). Talavera et al. previously identified 15 major glycoside derivatives including those of delphinidin, cyanidin, petunidin, peonidin and malvidin in Antho 50. In order to determine the proportion of the different anthocyanidins, an UPLC-PDA analysis of the Antho 50 hydrolyzed extract was performed. The Antho 50 content of delphinidin was 102.62 ± 4.87 mg/g, cyanidin 91.05 ± 3.95 mg/g, petunidin 75.99 ± 3.93 mg/g, pelargonidin 1.32 ± 0.05 mg/g, peonidin 9.51 ± 0.44 mg/g and malvidin 84.31 ± 4.73 mg/g. Furthermore, an UPLC-PDA was performed to quantify anthocyanins in their native forms. The Antho 50 content of delphinidin-3-O-glucoside was 89.17 ± 1.67 mg/g, delphinidin-3-O-glucoside 42.60 ± 1.30 µg/mg, cyanidin-3-O-glucoside 2.36 ± 0.10 µg/mg, petunidin-3-O-glucoside 32.94 ± 0.14 µg/mg and malvidin-3-O-glucoside 31.93 ± 0.36 µg/mg.

In order to determine the pro-apoptotic activity of pure anthocyanins, B CLL cells were incubated for 24 h with 30 or 100 µM of six commercially available anthocyanins: cyanidin-3-O-glucoside (1), cyanidin-3-O-galactoside (2), cyanidin-3-O-rutinoside (3), delphinidin-3-O-glucoside (4), delphinidin-3-O-galactoside (5) and delphinidin-3-O-rutinoside (6) (Fig. 2A). Then, the level of apoptosis was determined by flow cytometry. Treatment of B CLL cells with glucoside and rutinoside delphinidin derivatives increased the percentage of apoptotic cells, whereas delphinidin-3-O-galactoside and the cyanidin derivatives had only minor effects (Fig. 2B).

**Antho 50 induces an early caspase 3 activation and UHRF1 down-regulation in B CLL cells independently of the status of tumor suppressor genes p53 and p73.** Activation of caspase-dependent cascade leading to apoptosis has been involved in polyphenolic extracts-mediated cell death in cancer cells including leukaemia 17–20. We therefore determined the involvement of activated caspase 3, one of the main executors of apoptosis in the pro-apoptotic effect of Antho 50 in CLL cells (Fig. 3). Exposure of cells to 75 µg/mL of Antho 50 induced a time-dependent caspase 3 activation (Fig. 3). A slight increased expression of activated caspase 3 was observed already at one h and thereafter the signal increased progressively at least until 6 h (Fig. 3).

UHRF1 (Ubiquitin-like containing PHD and ring finger domains 1), a potent oncogene overexpressed in many human cancer cells, has been shown to play an important role in the epigenetic silencing of various tumor suppressor genes 21–23. Several reports have indicated that UHRF1 overexpression promotes proliferation of cancer cells by inhibiting apoptosis suggesting that this oncogene is a new therapy target for cancer cells, including leukaemia 21–23. As shown in Fig. 3, treatment of CLL cells with Antho 50 induced a decrease in UHRF1 expression accompanied by progressive activation of caspase 3 providing further evidence for the pro-apoptotic properties of Antho 50. These results suggest that Antho 50-induced apoptosis is linked to a rapid caspase 3 activation and UHRF1 down-regulation in CLL cells. To characterize the Antho 50-induced pro-apoptotic signaling pathway leading to caspase 3 activation, the levels of the tumor suppressor proteins p53 and p73 were determined. As shown in Fig. 3, the levels of p53 remained either unchanged or decreased in most CLL cells samples (CLL1, CLL2, CLL4, and CLL11). In the samples isolated from patients 3 and 5, an increase in p53 expression was observed at 6 h and caspase 3 activation at 3 h (Fig. 3). The level of p73, a pro-apoptotic member of the p53 family was undetectable or unchanged in 4 out of 6 CLL samples (Fig. 3). In the case of CLL 2, a pronounced increase in the level of p73 was observed at 6 h and caspase 3 activation at 1 h, and in the case of CLL 1, an increased level of p73 was observed in parallel with caspase 3 activation (Fig. 3). Taken together, these results suggest that the pro-apoptotic cellular response of CLL cells to Antho 50 involves caspase 3 activation and UHRF1 down-regulation predominantly via p53- and p73-independent pathways.

**Antho 50 induces Bcl-2 down-regulation associated with Bad (Bcl-2-associated death promoter) dephosphorylation.** The Bcl-2 family plays a key regulatory role in cellular responses to treatment via its pro- and anti-apoptotic properties 24. The anti-apoptotic protein Bcl-2 is overexpressed in several hematological malignancies including CLL and this overexpression is considered primarily responsible for defective apoptosis in CLL 25. We therefore evaluated the effect of Antho 50 treatment on the expression of two major members of the Bcl-2 family, Bcl-2 and p-Bad in cells from 3 CLL patients. As shown in Fig. 4A, a reduced Bcl-2 level was observed in CLL cells as a
Function of the treatment time with Antho 50. The down-regulation of Bcl-2 was accompanied by a reduction of cell viability starting at 1 h (Fig. 4B).

Since the inactivation of p-Bad via its dephosphorylation induces Bcl-2 down-regulation leading to apoptosis, the state of p-Bad was examined in response to Antho 50 treatment. Antho 50 treatment induced an early pronounced dephosphorylation of Bad starting at 1 h, which was followed with the down-regulation of Bcl-2 (Fig. 4A). Since p-Akt can phosphorylate Bad at Ser112 and Ser136 promoting survival, the potential of Antho 50 to inhibit the constitutive phosphorylation of Akt in CLL cells was examined. As indicated in Fig. 4A Antho 50 caused dephosphorylation of Akt at Ser473 within 1 h. These findings suggest that Antho 50 treatment causes dephosphorylation of Akt at Ser473 leading to the subsequent dephosphorylation of Bad, and ultimately the down-regulation of Bcl-2 producing activation of the caspase 3-related apoptotic pathway.

Antho 50 affects apoptosis-regulating proteins in CLL cells through a redox-sensitive mechanism. To determine whether the intracellular formation of ROS is a key event in the Bad/Bcl-2 deregulation leading to activation of the caspase 3-related pro-apoptotic signaling pathway in response to Antho 50, the effect of various antioxidants were tested. Exposure of cells isolated from patient 11, 26, 20 and 18 with PEG-catalase markedly reduced the Antho 50-induced dephosphorylation of Bad and down-regulation of Bcl-2 at 6 h (Fig. 6). Native SOD and catalase affected only slightly or had no such effect on p-Bad and Bcl-2 (Fig. 6). The Antho 50-induced activation of caspase 3 was inhibited in CLL cells CLL11, 6 and 20 (Fig. 7) and CLL9 and 10 (data not shown) in the presence of PEG-catalase as well as the down-regulation of UHRF1 in CLL11, 6 and 20 (Fig. 7). In contrast, native SOD and catalase affected only slightly or not at all both signals (Fig. 7). Altogether, these findings indicate that Antho 50 triggers apoptosis in CLL cells through a redox-sensitive activation of the caspase 3-related pro-apoptotic pathway possibly through Bad dephosphorylation and Bcl-2 down-regulation.

**Discussion**

Among hematological cancers, CLL is considered as a characteristic example of a neoplasia caused by the failure of apoptosis. Because of the important chemotherapy resistance and drug toxicity observed in treatment of this malignancy, there is a need for development of new therapeutic approaches. The Bcl-2 family proteins have a central role in the regulation of apoptosis.
role in CLL cell survival and chemotherapy resistance, making Bcl-2 inhibition as a potent target to induce apoptosis in CLL cells. The present study indicates that a polyphenol-rich extract (Antho 50) decreased cell viability and induced concentration- and time-dependent apoptosis in cells isolated from CLL patients. Interestingly, Antho 50 had no or only a weak effect in PBMC isolated from healthy subjects. The present study also sheds light onto the mechanism underlying the Antho 50-induced apoptosis in B CLL cells.

Pharmacological inhibition of ROS formation indicated the involvement of a redox-sensitive event in the caspase 3-related pathway in Antho 50-induced apoptosis of B CLL cells. The present study is in good agreement with recent reports indicating that anthocyanins induce mainly a caspase 3-dependent apoptosis in cell lines derived from colorectal cancer, and monocytic and promyelocytic hematological malignancies. The present findings extend these observations to the most frequent hematological malignancy, CLL, as indicated by the observations with cells from 30 patients.

The present findings provide evidence for a molecular action of Antho 50 in CLL involving activation of the caspase 3-related apoptotic pathway, as a result of down-regulation of Bcl-2 subsequent to Bad dephosphorylation. They further indicate that a rapid formation of ROS is involved in Antho 50-induced apoptosis. It is well-known that activation of Akt promotes cell survival by targeting several proteins involved in the regulation of apoptosis such as the pro-apoptotic Bcl-2 family member Bad. The present findings indicate that Antho 50-mediated rapid dephosphorylation of Akt is associated with dephosphorylation of Bad protein at Ser112 and reduced cell viability. It has been shown that the dephosphorylation of Bad promotes cell death by interacting with the anti-apoptotic protein Bcl-2 causing its down-regulation, which allows the activation of the mitochondria-mediated pro-apoptotic pathway leading to caspase 3 activation and cell death. Antho 50 rapidly induced Bad dephosphorylation in parallel with Bcl-2 down-regulation, caspase 3 activation and apoptosis. Previous reports have also indicated that polyphenolic compounds such as resveratrol, quercetin, curcumin, carnosic acid, and silybin induced apoptosis via caspase 3 activation in leukaemia cells.

In addition, Antho 50 caused down-regulation of the epigenetic integrator UHRF1, an anti-apoptotic protein which is overexpressed in many human cancer cells and plays an important role in the epigenetic silencing of various tumor suppressor genes including p16, hMLH1 and RB1. The histone deacetylase (HDAC) inhibitor valproate has been shown to act synergistically with fludarabine and cladribine, two clinically used anticancer drugs in the

![Figure 4](https://www.nature.com/scientificreports/srep08996)

**Figure 4** | Antho 50 induces dephosphorylation of Akt at Ser473, Bad at Ser112 and down-regulation of Bcl-2 in B CLL cells. Cells were incubated with Antho 50 at 75 μg/mL for the indicated times. The expression of the p-Akt, p-Bad and Bcl-2 was studied by Western blot (A, upper panel) and their expression levels were analyzed by densitometry and represented as percentage compared with control (A, lower panel). Cell viability was assessed by cell counting using the trypan blue dye exclusion assay (B). The control (Ctr) represents untreated cells harvested at 6 h. The data are representative of cells from three CLL patients.
Figure 5 | Antho 50 decreases cell viability and triggers apoptosis in B CLL cells through generation of ROS. Cells were exposed to Antho 50 (75 μg/mL) for different times (A) or to various inhibitors of ROS (B) for 30 min before the addition of Antho 50 (75 μg/mL) for 1 h. The formation of ROS was assessed by flow cytometry after incubation with the redox-sensitive fluorescent probe DHE. Cells were incubated with various inhibitors of ROS for 30 min before the addition of Antho 50 (75 μg/mL) for 6 h for cell viability analysis (C) or for 24 h before the determination of apoptosis (D). The control (Ctr) represents untreated cells harvested at 6 h. The data are representative of cells from three CLL patients for ROS analysis, three CLL patients for cell viability, and four CLL patients for apoptosis analysis.

Figure 6 | Antho 50 affects p-Bad and Bcl-2 proteins through a ROS-dependent mechanism. B CLL cells were exposed to either PEG-catalase (500 U/mL), catalase (500 U/mL), or SOD (500 U/mL) for 30 min before the addition of Antho 50 (75 μg/mL) for the indicated times. The expression of p-Bad and Bcl-2 was studied using Western blot and their expression levels were analyzed by densitometry and represented as percentage compared with control (Ctr). The control represents untreated cells harvested at the latest time point. The data are representative of four CLL patients.
treatment of CLL cells. Several reports have indicated that the anti-cancer drugs-induced inhibition of UHRF1 activity and/or expression might prevent the action of two of its preferred partners, namely HDAC1 (histone deacetylase 1) and DNMT1 (DNA methyltransferases), leading to re-expression of several tumor suppressor genes and thus allowing cancer cells to undergo apoptosis. In agreement with these observations, Antho 50 induced UHRF1 down-regulation, such a response may lead to reduced HDAC1 activity and as a consequence an increased apoptosis in CLL cells. Altogether, these findings suggest that Antho 50 induces a combined effect to kill CLL cells through caspase 3 activation and inhibition of UHRF1-regulated expression of several proteins involved in the repression of tumor suppressor genes.

Several reports have shown that polyphenolic compounds can increase ROS levels in human cancer cells, including leukemia and that this response is involved in the pro-apoptotic effect of red wine polyphenols, Aronia melanocarpa polyphenols and EGCG through UHRF1 down-regulation and caspase 3 activation in leukemia cells. Similarly, in the present study Antho 50 treatment of CLL cells rapidly induced an increased formation of ROS causing a reduction in cell viability and induction of apoptosis. The intracellular antioxidant PEG-catalase prevented the Antho 50-induced formation of ROS, reduction in cell viability and induction of apoptosis. The intracellular antioxidant PEG-catalase prevented the Antho 50-induced formation of ROS, reduction in cell viability and induction of apoptosis indicating a determinant role of ROS. In addition, the antioxidant PEG-catalase inhibited also the Antho 50-induced Bad dephosphorylation, Bcl-2 and UHRF1 down-regulation and caspase 3 activation providing further evidence that ROS play a key role in the Antho 50-induced apoptosis in CLL cells.

Polyphenols, particularly anthocyanins, have been reported to mediate the pro-apoptotic properties of different berries in various...
types of cancer cells, including those from colon tumors and leukemia. Our findings have identified the glucoseos and rutinoside derivatives of delphinin as active components of Antho 50 involved in the induction of apoptosis. Katsumi et al. also observed that delphinin strongly inhibited the growth of HL60 human promyelocytytic leukemia cells whereas cyanind had little effect. Altogether, these observations suggest that a hydroxyl group on position 5' of the B ring is a key structural characteristic involved in B CLL cytotoxicity. Since Antho 50 is a complex mixture of phytochemicals, and the pro-apoptotic effect of the extract is superior to that attributable to two major anthocyanins (delphinidin-3-O-glucoside and delphinidin-3-O-rutinoside) of Antho 50, anthocyanins and possibly other polyphenols, as flavonors and chlorogenic acid, might act in synergy to induce apoptosis in B CLL cells.

In conclusion, the present study highlights the potential of Antho 50 to induce a redox-sensitive apoptosis in CLL cells with little effect on healthy PBMC. Delphinin-3-O-glucoside and delphinidin-3-O-rutinoside were identified as active anthocyanins. It further suggests that Bcl-2 which is known to protect CLL cells from apoptosis, is a major target for Antho 50 and that its degradation via Bad death phosphorylation leads to caspase 3 activation (Fig. 8).
Acknowledgments

The authors would like to thank the "Alsace Contre le Cancer" for financial support. A.J.L.G. received a fellowship by Alfonso Martín Escudero Foundation.

Author contributions

M.A., A.J.L.G., I.D., A.L., C.K., J.P. and S.R. carried out the experiments. V.S.K., R.H. and M.A. performed the study design, data acquisition and analysis and wrote the manuscript. L.M.F. and L.M. contributed to interpretation of data and study coordination.

Additional information

Competing financial interests: The authors declare no competing financial interests.

How to cite this article: Alhosin, M. et al. Bilberry extract (Antho 50) selectively induces redox-sensitive caspase 3-related apoptosis in chronic lymphocytic leukemia cells by targeting the Bcl-2/Bad pathway. Sci. Rep. 5, 8996; DOI:10.1038/srep08996 (2015).

This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder in order to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/